Risk factor
Resilient to price shocks
Profitability factor
Favourable price performance
About
Wockhardt Limited is a pharmaceutical and biotechnology enterprise specializing in the production and commercialization of active pharmaceutical ingredients, finished drug formulations, biosimilars, and vaccines. Its global footprint encompasses India, the United States, the United Kingdom, Ireland, Mexico, Russia, and other international markets. The company dedicates substantial research and development efforts to discovering new molecules, especially for infectious diseases, with notable projects including WCK 5222, WCK 4282, WCK 4873, WCK 771, WCK 2349, and WCK 6777. Among its biopharmaceutical offerings are Glaritus (an insulin analog), Wosulin (an r-DNA insulin), Wepox (a recombinant erythropoietin used to address anemia linked to cancer and chronic kidney failure), and Biovac-B (a hepatitis B vaccine). Additionally, Wockhardt provides contract manufacturing solutions for sterile injectables, lyophilization, and various other dosage forms, alongside offering specialized research services. Established in 1967, the company maintains its headquarters in Mumbai, India, and functions as a subsidiary of Themisto Trustee Company Private Limited.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA